The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 27, 2007

Filed:

Jun. 27, 2002
Applicants:

Rachel E. Meyers, Newton, MA (US);

Mark Williamson, Saugus, MA (US);

Kevin R. Leiby, Natick, MA (US);

Rosana Kapeller-libermann, Chestnut Hill, MA (US);

Peter J. Olandt, Newton, MA (US);

Kyle J. Macbeth, Boston, MA (US);

Laura A. Rudolph-owen, Jamaica Plain, MA (US);

Fong-ying Tsai, Newton, MA (US);

John J. Hunter, Somerville, MA (US);

Inventors:

Rachel E. Meyers, Newton, MA (US);

Mark Williamson, Saugus, MA (US);

Kevin R. Leiby, Natick, MA (US);

Rosana Kapeller-Libermann, Chestnut Hill, MA (US);

Peter J. Olandt, Newton, MA (US);

Kyle J. MacBeth, Boston, MA (US);

Laura A. Rudolph-Owen, Jamaica Plain, MA (US);

Fong-Ying Tsai, Newton, MA (US);

John J. Hunter, Somerville, MA (US);

Assignee:

Millennium Pharmaceuticals, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 1/00 (2006.01); C07H 5/00 (2006.01); C07H 19/00 (2006.01); C07H 21/00 (2006.01); C07H 21/02 (2006.01); C08B 37/00 (2006.01); C12Q 1/68 (2006.01); C12P 21/06 (2006.01); C12P 19/34 (2006.01); C12N 1/12 (2006.01); C12N 1/20 (2006.01); C12N 15/00 (2006.01); C12N 15/06 (2006.01);
U.S. Cl.
CPC ...
Abstract

The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 gene has been introduced or disrupted. The invention still further provides isolated 33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 proteins, fusion proteins, antigenic peptides and anti-33877, 47179, 26886, 25552, 32132, 32244, 23680, 32624, 47174, 60491, 46743, 27417, 27960, 32252, or 53320 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.


Find Patent Forward Citations

Loading…